Results 11 to 20 of about 1,955 (223)

Burosumab in Unidentifiable Tumor‐Induced Osteomalacia [PDF]

Clinical Case Reports
Tumor‐induced osteomalacia (TIO) can be challenging due to underlying tumors being either unresectable or unidentifiable. Burosumab, an anti‐FGF23 monoclonal antibody, has been proven to be effective in treating TIO but is currently not subsidized for ...
Yi Shan Der, Santosh Chaubey, Anna Mclean, Yasmin Trinh, Shelley Pember, Ashim Sinha   +5 more
doaj   +3 more sources

Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels [PDF]

, 2023
BACKGROUND: Burosumab, an antifibroblast growth factor 23 monoclonal antibody, improves rickets severity, symptoms and growth in children with X-linked hypophosphataemia (XLH) followed up to 64 weeks in clinical trials.
Allgrove, Jeremy, Bockenhauer, Detlef, Hayes, Wesley, Lindsay, Timothy Alexander James, Marlais, Matko, Walker, Emma Yi Xiu   +5 more
core   +3 more sources

Burosumab therapy in children with x-linked hypophosphatemia [PDF]

Yearbook of Paediatric Endocrinology, 2018
BACKGROUND X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteomalacia, and skeletal deformities.
Boot, Annemieke M, Carpenter, Thomas O, Chen, Chao-Yin, Hogler, Wolfgang, Imel, Erik A, Kakkis, Emil, Linglart, Agnes, Mao, Meng, Martin, Javier San, Padidela, Raja, Portale, Anthony A, Skrinar, Alison, van\u27t Hoff, William, Whyte, Michael P   +13 more
core   +6 more sources

Burosumab - new potent treatment for X-linked hypophosphatemia and tumor-induced osteomalacia [PDF]

Journal of Education, Health and Sport, 2023
Introduction and purpose: Elevated FGF23 in X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) leads to systemic hypophosphatemia, several musculoskeletal manifestations and rickets in children. In this review we describe advances in
Magda Wojtuś, Sebastian Tomaszuk, Karolina Wąsik   +2 more
doaj   +3 more sources

Effect of burosumab conversion on calciuria and nephrocalcinosis in children with XLH: A real-world cohort study [PDF]

Bone Reports
Background: Burosumab, a monoclonal antibody to fibroblast growth factor 23 (FGF23), is effective for X-linked hypophosphatemic rickets (XLH). Renal effects, particularly calciuria and nephrocalcinosis, remain incompletely characterized. Methods: In this
Guido Filler, Harry Chandrakumaran, Funmbi Babalola, Dougenie Emile, Shih-Han Susan Huang, Robert Stein   +5 more
doaj   +2 more sources

Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study

Frontiers in Pediatrics
BackgroundX-linked hypophosphatemic rickets (XLH) is associated with uninhibited FGF23 activity, which leads to phosphaturia, hypophosphatemia and depressed active vitamin D (1,25OH2D) levels. Conventional treatment with phosphate supplements and vitamin
Shelly Levi, Daniel Landau, Daniel Landau, Miriam Davidovits, Miriam Davidovits, Mika Shapira Rootman, Avivit Brener, Avivit Brener, Shoshana Gal, Shoshana Gal, Yael Borovitz, Yael Borovitz, Ori Goldberg, Ori Goldberg, Ori Goldberg, Rachel Bello, Roxana Cleper, Roxana Cleper, Yael Lebenthal, Yael Lebenthal, Yael Levy-Shraga, Yael Levy-Shraga, Dov Tiosano, Dov Tiosano, Adi Chezana, Ravit Regev, Ravit Regev, Leonid Zeitlin, Leonid Zeitlin   +28 more
doaj   +2 more sources

Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UK. [PDF]

Calcif Tissue Int
X-linked hypophosphataemia (XLH) is a genetic phosphate-wasting disorder caused by excess fibroblast growth factor 23 (FGF23), which leads to skeletal morbidities, pain, stiffness, and impairments in physical function and health-related quality of life ...
Bubbear J, Lachmann R, Murphy E, Krishna G, Clunie GPR, Walsh J, Schini M, Salam S, Roy M, Finezilber Y, Mathieson L, Hayes V, Johnson B, Logan G, Stevens D, Davda R, Nixon M, Bowden A, Barham H, Keen R.   +19 more
core   +3 more sources

Use of burosumab in McCune Albright syndrome: case report and review of literature in mosaic disorders with FGF23 overproduction [PDF]

Frontiers in Endocrinology
Increased fibroblast growth factor 23 (FGF23) related mosaic syndromes include a spectrum of disorders sharing postzygotic mutations, skin involvement and dysplastic bone lesions.
Alessandro Barbato, Alessandro Barbato, Renato Vaiasuso, Renato Vaiasuso, Eugenio Trinati, Eugenio Trinati, Giulia Del Medico, Giulia Del Medico, Nicolò Chiti, Giampiero Igli Baroncelli, Stefano Stagi, Stefano Stagi   +11 more
doaj   +2 more sources

Experts’ consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan [PDF]

J Endocrinol Invest
Purpose: X-linked hypophosphatemia (XLH) is a rare hereditary skeletal disorder that may be very disabling and significantly impacting the quality of life throughout the lifespan.
Andrea, Palermo, Anna, Grandone, Barbara, Ruggiero, Cristina, Eller-Vainicher, Danilo, Fintini, Elena, Castellano, Filomena, Cetani, Francesca, Pigliaru, Francesco, Emma, Giorgia, Grassi, Giuseppe, Vezzoli, I, Baroncelli Giampiero, Laura, Gianotti, Luisa, Brandi Maria, Maddalena, Ruggeri Rosaria, Manuela, Caruso Nicoletti, Marco, Barale, Marco, Pitea, Massimo, Procopio, Natascia, Di Iorgi, Pasquale, Comberiati, Sabrina, Corbetta, Sandro, Giannini, Silvia, Carrara, Stefano, Mora, Stefano, Stagi, Valentina, Camozzi, Vincenzo, Rochira   +27 more
core   +2 more sources

Office blood pressure and obesity in children with X-linked hypophosphatemia [PDF]

Calcif Tissue Int
X-linked hypophosphatemia (XLH) is the most common inherited form of hypophosphatemic rickets. Children with XLH have an increased risk of obesity, which may promote high blood pressure, but data on blood pressure in XLH are inconclusive.
Böckmann, Ineke, Derichs, Ute, Dunstheimer, Desiree, Evers, Katrina, Freiberg, Clemens, Grohmann-Held, Karina, Haffner, Dieter, Heger, Sabine, Hiort, Olaf, John-Kroegel, Ulrike, Jorch, Norbert, Kemper, Markus J., Leifheit-Nestler, Maren, Metzing, Oliver, Patzer, Ludwig, Rehberg, Mirko, Richter-Unruh, Annette, Schlingmann, Karl Peter, Schmid, Elmar, Schnabel, Dirk, Spartà, Giuseppina, Staude, Hagen, Weitz, Marcus, Wühl, Elke, Zivicnjak, Miroslav   +24 more
core   +2 more sources